姜黄素作为癌症化学预防剂而获得认可，目前已用于人类。然而，值得注意的是，针对前列腺癌治疗进行的临床试验数量有限。动物模型是增强我们对人类疾病机制和病因学的理解的宝贵工具。本研究的目的是检查姜黄素在体内的抗前列腺癌作用，以了解其当前的研究状况和潜在的临床适用性。我们的方法涉及对姜黄素和前列腺癌相关的动物研究进行系统探索，如 PubMed 中所述， Web of Science、Embase、Cochrane Library、CNKI、万方数据库、维普数据库和SinoMed，截至2023年9月3日。使用SYRCLE动物研究偏倚风险工具评估偏倚风险。使用 RevMan 5.3 合并结果。对涵盖 263 个小鼠移植肿瘤模型的 17 项研究进行了综合分析。这项荟萃分析的结果表明，与对照组相比，姜黄素对小鼠前列腺癌肿瘤体积表现出优异的抑制作用（标准化平均差[SMD]：1.16，95％置信区间[CI]：0.52，1.80 ，p < 0.001）。此外，姜黄素对小鼠前列腺癌肿瘤重量具有更有效的抑制作用（SMD：-3.27，95% CI：-4.70，-1.83，p < 0.001）。此外，在肿瘤抑制率方面，姜黄素表现出更高的功效（SMD：0.25，95％CI：0.23，0.27，p <0.001）。此外，姜黄素更有效地抑制 PCNA mRNA (SMD: -3.11, 95% CI: -4.60, -1.63, p < 0.001) 和 MMP2 mRNA (SMD: -3.19, 95% CI: 5.85, -0.53, p < 0.001)姜黄素表现出对前列腺肿瘤生长的抑制特性，并对前列腺癌的治疗显示出有益的作用，从而为进一步的临床研究提供了证据。重要的是要承认，纳入的动物研究表现出相当大的异质性，主要是因为纳入的研究数量有限。因此，需要进行额外的随机对照试验来全面评估姜黄素在人体中的功效。(https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023464661)，标识符(CRD42023464661)。版权所有© 2024 王、张和陈。

Curcumin is gaining recognition as an agent for cancer chemoprevention and is presently administered to humans. However, the limited number of clinical trials conducted for the treatment of prostate cancer is noteworthy. Animal models serve as valuable tools for enhancing our understanding of disease mechanisms and etiology in humans. The objective of this study was to examine the anti-prostate cancer effects of curcumin in vivo for comprehending its current research status and potential clinical applicability.Our methodology involved a systematic exploration of animal studies pertaining to curcumin and prostate cancer, as documented in PubMed, Web of Science, Embase, Cochrane Library, CNKI, Wanfang database, Vip database, and SinoMed, up to 03 September 2023. Risk of bias was assessed using the SYRCLE Animal Study Risk of Bias tool. The results were combined using the RevMan 5.3.A comprehensive analysis was conducted on 17 studies encompassing 263 mouse transplantation tumor models. The findings of this meta-analysis demonstrated that curcumin exhibited a superior inhibitory effect on the volume of prostate cancer tumors in mice compared to the control group (standardized mean difference [SMD]: 1.16, 95% confidence interval [CI]: 0.52, 1.80, p < 0.001). Additionally, curcumin displayed a more effective inhibition of mice prostate cancer tumor weight (SMD: -3.27, 95% CI: -4.70, -1.83, p < 0.001). Furthermore, in terms of tumor inhibition rate, curcumin exhibited greater efficacy (SMD: 0.25, 95% CI: 0.23, 0.27, p < 0.001). Moreover, curcumin more effectively inhibited PCNA mRNA (SMD: -3.11, 95% CI: -4.60, -1.63, p < 0.001) and MMP2 mRNA (SMD: -3.19, 95% CI: 5.85, -0.53, p < 0.001).Curcumin exhibited inhibitory properties towards prostate tumor growth and demonstrated a beneficial effect on prostate cancer treatment, thereby offering substantiation for further clinical investigations. It is important to acknowledge that the included animal studies exhibited considerable heterogeneity, primarily because of the limited number of studies included. Consequently, additional randomized controlled trials are required to comprehensively assess the efficacy of curcumin in humans.(https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023464661), identifier (CRD42023464661).Copyright © 2024 Wang, Zhang and Chen.